KCM
GILD icon

Kennedy Capital Management’s Gilead Sciences GILD Stock Holding History

Kennedy Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Sell
90,643
-621
-0.7% -$81.8K 0.2% 175
2026
Q1 		$12.7M Sell
91,264
-4,139
-4% -$580K 0.27% 135
2025
Q4 		$11.7M Buy
95,403
+1,128
+1% +$137K 0.25% 150
2025
Q3 		$10.5M Buy
94,275
+15,234
+19% +$1.73M 0.23% 150
2025
Q2 		$8.76M Sell
79,041
-41
-0.1% -$4.36K 0.21% 164
2025
Q1 		$8.86M Sell
79,082
-3,931
-5% -$406K 0.21% 163
2024
Q4 		$7.67M Buy
83,013
+16,603
+25% +$1.49M 0.17% 203
2024
Q3 		$5.57M Buy
66,410
+5,023
+8% +$383K 0.12% 285
2024
Q2 		$4.21M Buy
61,387
+21,167
+53% +$1.41M 0.09% 362
2024
Q1 		$2.95M Buy
+40,220
New +$3.09M 0.06% 449

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kennedy Capital Management's GILD Position: Q2 2026 in Review

Kennedy Capital Management reduced its Gilead Sciences (GILD) stake by 0.68% in Q2 2026, selling an estimated $81.8K and leaving 90,643 shares worth $11.5M. The position accounts for 0.2% of the portfolio, ranked #175.

Kennedy Capital Management first reported a position in GILD in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.7M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Kennedy Capital Management held 90,643 shares of Gilead Sciences worth $11.5M as of Q2 2026.
  • Kennedy Capital Management sold 621 Gilead Sciences shares in Q2 2026, an estimated $81.8K.
  • Gilead Sciences made up 0.2% of Kennedy Capital Management's portfolio in Q2 2026, its #175 holding.
  • Kennedy Capital Management first reported a position in Gilead Sciences in Q1 2024 and has held it in 10 quarters since.
  • Kennedy Capital Management's Gilead Sciences position peaked at $12.7M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.